NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time

By June 9, 2015

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary non-antibiotic antimicrobial products, will host an investment community conference call today, June 9th, 2015.

Management will discuss the attributes of its FDA-cleared intelli-Case for safely disinfecting contact lenses with hydrogen peroxide announced in its press release issued June 4, 2015 and share its initial commercialization strategy.  The conference call will feature presentations from the following leading key opinion leaders in the field of eye care:

Arthur B. Epstein, OD, FAAO, FABCO, FBCLA, DPNAP (2014). Dr. Epstein is co-founder, head of the Dry-Eye–Ocular Surface Disease Center and Director of Clinical Research of the Phoenix Eye Care.  He serves as an Adjunct Associate Professor at Midwestern University, Arizona College of Optometry Institute and is the contributing Editor for Review of Optometry, Executive Editor of Review of Cornea and Contact Lenses, and founder and Chief Medical Editor of Optometric Physician.  Dr. Epstein has presented more than a 1,000 invited lectures.  He is a Fellow of the British Contact Lens Association, a Distinguished Practitioner of the National Academies of Practice, a Fellow of the American and New York Academies of Optometry and a full member of the International Society of Contact Lens Specialists.  Dr. Epstein is a member of the NovaBay Optometry Advisory Board.

Steven Lichtenstein, MD, FAAP, FACS, FAAO.  Dr. Lichtenstein is Medical Director of Pediatric Ophthalmology Children’s Hospital of Illinois, Peoria as well as Associate Clinical Professor in the Division of Ophthalmology, University of Illinois College of Medicine at Peoria and Chicago. Dr. Lichtenstein received his M.D. degree from the University of Louisville School of Medicine, and served his residency in the Department of Ophthalmology and Visual Science at Yale University and received his fellowship training in the Department of Ophthalmology at Children’s Hospital Boston, Harvard Medical School. He has published more than 25 peer-reviewed articles mostly on various aspects of pediatric ocular infections.  Dr. Lichtenstein is a member of NovaBay Ophthalmic Advisory Board.

DATE: Tuesday, June 9, 2015
TIME: 12:00 p.m. (noon) Eastern time
9:00 a.m. Pacific time
DIAL IN: 866-880-4999 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 57071355

The live call also will be available at http://novabay.com/investors/events.  A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time June 23, 2015, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 57071355. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care,, and CELLERX®  for the aesthetic dermatology market, cleared by the FDA as a 510(k) medical device; and its AGANOCIDE® compounds, led by AURICLOSENE™.

NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).

NovaBay has received FDA-clearance of its intelli-Case, a highly innovative, easy-to-use device for use with hydrogen peroxide disinfection solutions with soft and Rigid Gas Permeable (RGP) contact lenses.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

For NovaBay Avenova purchasing information, please contact:
Email us
Toll Free: 1-800-890-0329
www.avenova.com

From the Company
Thomas J. Paulson  
Chief Financial Officer
510-899-8809
Contact Thomas Paulson

Investor Contact
LHA
Jody Cain
310-691-7100
jcain@lhai.com

TOP